You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Merestinib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Merestinib?

Merestinib is an investigational drug.

There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2016.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Jacqueline Garcia, MD.

There are nine US patents protecting this investigational drug and two hundred and twenty international patents.

Recent Clinical Trials for Merestinib
TitleSponsorPhase
Merestinib on Bone Metastases in Subjects With Breast CancerEli Lilly and CompanyPhase 1
Merestinib on Bone Metastases in Subjects With Breast CancerUniversity of UtahPhase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaEli Lilly and CompanyPhase 1

See all Merestinib clinical trials

Clinical Trial Summary for Merestinib

Top disease conditions for Merestinib
trials0112233Neoplasm MetastasisNeoplasmsCarcinomaLeukemia, Myeloid[disabled in preview]
Top clinical trial sponsors for Merestinib
trials012345678Eli Lilly and CompanyDana-Farber Cancer InstituteJacqueline Garcia, MD[disabled in preview]

See all Merestinib clinical trials

US Patents for Merestinib

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Merestinib ⤷  Subscribe Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Subscribe
Merestinib ⤷  Subscribe Methods of treating a neuroendocrine tumor SCRIPPS HEALTH (San Diego, CA) ⤷  Subscribe
Merestinib ⤷  Subscribe Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Subscribe
Merestinib ⤷  Subscribe Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Subscribe
Merestinib ⤷  Subscribe Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) ⤷  Subscribe
Merestinib ⤷  Subscribe Macrocylic compounds as ROS1 kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Subscribe
Merestinib ⤷  Subscribe PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 7 of 7 entries

International Patents for Merestinib

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Merestinib Australia AU2017261372 2036-05-05 ⤷  Subscribe
Merestinib Canada CA3023278 2036-05-05 ⤷  Subscribe
Merestinib China CN107847398 2036-05-05 ⤷  Subscribe
Merestinib European Patent Office EP3452003 2036-05-05 ⤷  Subscribe
Merestinib European Patent Office EP3981392 2036-05-05 ⤷  Subscribe
Merestinib Hong Kong HK1249728 2036-05-05 ⤷  Subscribe
Merestinib Japan JP2019520866 2036-05-05 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 7 of 7 entries

Development Update and Market Projection for Merestinib

Introduction to Merestinib

Merestinib, also known as LY2801653, is an experimental cancer drug developed by Eli Lilly. It is a small molecule inhibitor targeting the MET receptor tyrosine kinase, as well as several other kinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2. This broad spectrum of inhibition makes merestinib a promising candidate for treating various types of cancers[5].

Current Development Status

Phase II Trials and Termination

A recent development in the merestinib pipeline involves the termination of an investigator-led Phase II trial in solid tumors. This trial, conducted by the Dana-Farber Cancer Institute, was halted due to funding issues. The termination led to a significant drop in the Phase Transition Success Rate (PTSR) for merestinib in solid tumors, from 26% to 11%[1].

Other Ongoing and Completed Trials

Despite the setback, merestinib has been evaluated in other clinical settings. For instance, a Phase I study combining merestinib with ramucirumab (an anti-VEGFR2 monoclonal antibody) showed promising results in patients with metastatic colorectal cancer (mCRC). The combination was found to be tolerable and may provide clinical benefit, with 52% of patients achieving stable disease and a median progression-free survival of 3.3 months[3].

Merestinib has also been part of Phase II clinical trials for advanced biliary tract cancer and non-small cell lung cancer, which were initiated in 2016. However, the status of these trials, especially the one for biliary tract cancer expected to complete in April 2018, is not up-to-date in recent reports[5].

Safety and Efficacy

Safety Profile

The safety profile of merestinib, particularly when combined with ramucirumab, has been generally well-tolerated. The Phase I study reported that the most common grade 3 or higher treatment-related adverse events included fatigue, increased blood alkaline phosphatase, diarrhea, and hypertension. One patient discontinued treatment due to cholestatic hepatitis, but overall, the combination did not show significant drug-drug interactions[3].

Efficacy Data

While the combination of merestinib and ramucirumab did not result in complete or partial responses, it did achieve stable disease in approximately 50% of the patients. This suggests potential clinical benefit, especially in heavily pretreated populations. The median overall survival was 8.9 months, indicating some level of efficacy in this patient group[3].

Market Projection

Oncology Drugs Market

The global oncology drugs market is experiencing rapid growth, driven by innovative treatments and increasing investments in cancer research. The market is projected to grow from $220.80 billion in 2024 to $518.25 billion by 2032, at a CAGR of 11.3%[4].

Targeted Therapy Segment

Merestinib, as a targeted therapy agent, falls within a segment that is expected to dominate the oncology drugs market. Targeted drugs, which minimize off-target side effects, are gaining preference due to their efficacy and safety profiles. The rising number of pipeline candidates and regulatory approvals for new cancer drugs will further fuel the growth of this segment[4].

Checkpoint Inhibitor Refractory Cancer Market

Although merestinib is not specifically a checkpoint inhibitor, the growth in the checkpoint inhibitor refractory cancer market is indicative of the broader trend in immunotherapy and targeted treatments. This market is projected to grow at a CAGR of 11.26% from 2023 to 2033, reaching $112.43 billion by 2033. This growth is driven by the increasing number of FDA approvals for checkpoint inhibitors and their expanding indications across various cancer types[2].

Key Takeaways

  • Development Status: Merestinib's Phase II trial in solid tumors was terminated due to funding issues, but other trials, such as the combination with ramucirumab, show promise.
  • Safety and Efficacy: The drug has a tolerable safety profile and potential clinical benefit, especially in combination therapies.
  • Market Growth: The oncology drugs market, particularly the targeted therapy segment, is expected to grow significantly, providing a favorable environment for merestinib if it progresses successfully.
  • Market Size: The global oncology drugs market is projected to reach $518.25 billion by 2032, with targeted therapies playing a dominant role.

FAQs

1. What is merestinib and how does it work? Merestinib is an experimental cancer drug that inhibits the MET receptor tyrosine kinase and several other kinases, making it a targeted therapy for various cancers.

2. What was the outcome of the Phase II trial in solid tumors? The Phase II trial in solid tumors was terminated due to funding issues, leading to a drop in the Phase Transition Success Rate (PTSR) for merestinib.

3. How safe is the combination of merestinib and ramucirumab? The combination of merestinib and ramucirumab has been found to be generally well-tolerated, with common adverse events including fatigue, increased blood alkaline phosphatase, diarrhea, and hypertension.

4. What is the projected growth of the oncology drugs market? The global oncology drugs market is projected to grow from $220.80 billion in 2024 to $518.25 billion by 2032, at a CAGR of 11.3%.

5. How does merestinib fit into the broader oncology market trends? Merestinib, as a targeted therapy agent, aligns with the growing trend of targeted therapies in the oncology market, which are preferred for their efficacy and safety profiles.

Sources

  1. ClinicalTrialsArena: Pipeline Moves: Investigator-led trial of Lilly's merestinib in solid tumours terminated.
  2. Future Market Insights: Checkpoint Inhibitor Refractory Cancer Market Outlook - 2033.
  3. Oxford Academic: Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Patients with Metastatic Colorectal Cancer.
  4. Fortune Business Insights: Oncology Drugs Market Size, Share & Growth | Statistics [2032].
  5. Wikipedia: Merestinib.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.